CAROLINA-CARMELINA-Asia-analysis
CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
Search
new_analysis_nintedanib_SSc_ILD
Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
RE-LY-trial-publication-10-year-anniversary
Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
The Angels Initiative
The Angels Initiative helps hospitals around the world become ‘stroke-ready’ so that stroke patients can be treated as quickly and effectively as possible.
U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults
Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults
empa-reg-outcome-recurrent-events
EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Boehringer receives SBTi validation for CO2 reduction targets
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
Hypertension
Click here for more information on Hypertension
Brand of the Year Frontline pet parasiticides
FRONTLINE® Wins Brand of the Year Award for the Third Time in a row
Grow Your Skills
Great things in business are never done by one person; they’re done by a team of people
Overcoming heartworm disease for homeless pets
Heartworm-free pets soar to new lives. Together with our Greater Good Charity partners, our colleagues helped bring shelter dogs to forever homes.
Results for Jardiance EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
Lifelong learning at our Virtual Campus
The Virtual Campus of our Boehringer Ingelheim University supports our employees in their personalized lifelong learning.
Avian influenza 5 things you should know
Communities across the globe are faced with outbreaks of bird flu. We stand with poultry farmers and veterinarians and supports the effort against the disease
cat feline diabetes medication treatment eu approval
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
Anna Race
Anna Race, Sales Director, Human Pharma, UK & Ireland, tells us how a career in our Commercial Division helps her to make a difference.
Advances in vectored vaccines for poultry
Vaccine design technologies have made huge advances in recent years. One of the newer categories of vaccine, vectored vaccines, is overcoming challenges that conventional vaccines do not meet.
Jean-Michel Boers Appointed to PhRMA Board of Directors
Jean-Michel Boers Appointed to PhRMA Board of Directors
Performance Indicators
Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
vet scholars symposium
Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
What do you know about transboundary animal diseases
Transboundary animal diseases (TADs) are highly transmissible diseases of livestock that can impact veterinary public health preparedness.
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Aservo EquiHaler wins Pharmapack Award 2021
Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine